GHK-Cu is a naturally occurring copper peptide best known for its remarkable effects on skin, hair, and healing
With a slightly acidic pH close to that of healthy skin, this mask is made with only EWG green-graded ingredients
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
Axxams GLP-1 secretion assay: metabolic drug discovery from a different perspective Studies have shown that fatty acids and other endogenous ligands may engage with relevant GPCRs, including GPR40, GPR120, GPR119 and TGR5, to promote GLP-1 secretion
This is deprotonated forming a yellow compound that can be photometrically quantified at 414 nm directly revealing the concentration of free thiols
The prescription exists, but it does not reference a specific diagnosis
